ReviewCardiovascular diabetology. Endocrinology reports2026

Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.

Adir Alper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.